Rigor Reviewed

Rigor-Reviewed Manuscript

Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.

Name: Αlpha¹ Rigor Record — Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.
Item: Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.
Rating: 88
Author: Αlpha¹

Wang SX, Tao YL, Gao TS, Zhang N, Zhou GQ, Xie FY, Zhang Y, Guo R, Yang Y, Li YJ, Liang SQ, Zeng YC, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Liu LZ, Li HJ, Li JB, Wen HM, Sun Y, Tang LL, Liang XY, Ma J, Mao YP

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 5 high issues for “Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ReportingKey resources partially met−0.25★

Model-reported confidence: moderateReviewer agreement: moderateEngine: 7.29.0Source: full text

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Data look implausibly cleanAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a methodologically strong, pre-registered phase 3 non-inferiority RCT with a rigorous randomisation scheme, pre-specified power calculation, masked central assessors, transparent outcome reporting, and independently consistent recomputed statistics (13/14 consistent, no decision errors). The identified weaknesses are minor reporting gaps — analysis code only in a web appendix, some p-values reported as thresholds, no explicit CONSORT checklist reference, and a clear typographical error in Table 1 (Stage IVa '124 (448)') — none of which threatens the primary conclusions.

All three reviewers (independent runs of the same model) agreed on study type and on pass for scientific premise, study design, statistical analysis, and reporting transparency; they split 2-1 (majority pass) on biological variables, ethical approvals, and data code availability, and diverged three ways on key resources (adopted not applicable). The statistics component recomputed only a subset of tests (14 eligible; 13 consistent) — tests not recomputed are unverified, not confirmed. The citation check found 0 retracted and 0 undiscoverable references; the claim audit found 0 under-evidenced claims.

12 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 13 tests: 13 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 12 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites MRI-based studies showing MRLN metastasis rates below 0.6% and notes that traditional target delineation exposes pharyngeal constrictors to high doses, grounding the rationale. It acknowledges that prior guideline-based practice was anchored in two-dimensional era experience and that no other prospective study had explored this question, addressing gaps in prior work. The hypothesis follows logically: sparing the MRLN region should reduce dysphagia without compromising local control.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes its scientific foundation with extensive prior literature and a coherent mechanistic rationale.

Evidence

direct quote[Introduction, paragraph 1]

“Recently, several magnetic resonance imaging (MRI) based studies have shown that retropharyngeal lymph node involvement primarily occurs in the lateral group, with a metastasis rate of less than 0.6% in the medial group.”